FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601563721> ?p ?o ?g. }

• W2601563721 endingPage "82" @default.
• W2601563721 startingPage "82" @default.
• W2601563721 abstract "We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment.The medical records of 228 patients who underwent surgical resection and received adjuvant chemotherapy with trastuzumab for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer between January 2010 and December 2014 were reviewed. Approximately 25% of patients received DZR prior to each administration of doxorubicin during doxorubicin with cyclophosphamide (AC) chemotherapy. DZR was not administered during the 1-year trastuzumab maintenance period. Rates of cardiac events (reduction in left ventricular ejection fraction [LVEF] by 10% or more; reduction in absolute LVEF to <45%) and cardiac event-free duration (CFD) were examined. The trastuzumab interruption rate was also assessed.Twelve percent of patients experienced a cardiac event. Repeated-measures analysis of variance for ejection fraction revealed a significant main effect of time, and a significant group (DZR)×time interaction. The group treated with adjuvant chemotherapy and DZR experienced significantly lower frequencies of cardiac events than the adjuvant chemotherapy only group. In multivariate analysis, DZR administration was associated with significantly fewer cardiac events. Moreover, DZR administration was an independent good prognostic factor for CFD. Only one patient (2.3%) experienced early interruption of trastuzumab in the adjuvant chemotherapy with DZR group due to cardiac toxicity, whereas 10 patients (7.6%) experienced a trastuzumab stop event in the adjuvant chemotherapy only group.DZR is cardioprotective in HER2-positive breast cancer patients who received adjuvant chemotherapy with trastuzumab. A large cohort randomized trial is needed to determine if DZR has an effect on trastuzumab interruption and completion of 12-month trastuzumab. Because cardiac toxicity has a significant negative effect on trastuzumab maintenance and quality of life, DZR administration could be considered concomitantly with anthracycline-based adjuvant chemotherapy with trastuzumab." @default.
• W2601563721 created "2017-04-07" @default.
• W2601563721 creator A5018869195 @default.
• W2601563721 creator A5022604964 @default.
• W2601563721 creator A5065796888 @default.
• W2601563721 creator A5078331452 @default.
• W2601563721 creator A5090392492 @default.
• W2601563721 date "2017-01-01" @default.
• W2601563721 modified "2023-09-28" @default.
• W2601563721 title "Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab" @default.
• W2601563721 cites W1492360552 @default.
• W2601563721 cites W1833330468 @default.
• W2601563721 cites W1927299313 @default.
• W2601563721 cites W1957304651 @default.
• W2601563721 cites W1974647451 @default.
• W2601563721 cites W1996778928 @default.
• W2601563721 cites W2008347459 @default.
• W2601563721 cites W2028945760 @default.
• W2601563721 cites W2040935952 @default.
• W2601563721 cites W2079969054 @default.
• W2601563721 cites W2084196088 @default.
• W2601563721 cites W2095633632 @default.
• W2601563721 cites W2099067294 @default.
• W2601563721 cites W2100912472 @default.
• W2601563721 cites W2140074016 @default.
• W2601563721 cites W2141393790 @default.
• W2601563721 cites W2146384083 @default.
• W2601563721 cites W2150222021 @default.
• W2601563721 cites W2152647863 @default.
• W2601563721 cites W2159853440 @default.
• W2601563721 cites W2160797676 @default.
• W2601563721 cites W2171747665 @default.
• W2601563721 cites W2205841570 @default.
• W2601563721 cites W2411365689 @default.
• W2601563721 cites W2916315386 @default.
• W2601563721 cites W2916636570 @default.
• W2601563721 doi "https://doi.org/10.4048/jbc.2017.20.1.82" @default.
• W2601563721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5378583" @default.
• W2601563721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28382098" @default.
• W2601563721 hasPublicationYear "2017" @default.
• W2601563721 type Work @default.
• W2601563721 sameAs 2601563721 @default.
• W2601563721 citedByCount "16" @default.
• W2601563721 countsByYear W26015637212017 @default.
• W2601563721 countsByYear W26015637212018 @default.
• W2601563721 countsByYear W26015637212019 @default.
• W2601563721 countsByYear W26015637212020 @default.
• W2601563721 countsByYear W26015637212021 @default.
• W2601563721 countsByYear W26015637212022 @default.
• W2601563721 countsByYear W26015637212023 @default.
• W2601563721 crossrefType "journal-article" @default.
• W2601563721 hasAuthorship W2601563721A5018869195 @default.
• W2601563721 hasAuthorship W2601563721A5022604964 @default.
• W2601563721 hasAuthorship W2601563721A5065796888 @default.
• W2601563721 hasAuthorship W2601563721A5078331452 @default.
• W2601563721 hasAuthorship W2601563721A5090392492 @default.
• W2601563721 hasBestOaLocation W26015637211 @default.
• W2601563721 hasConcept C121608353 @default.
• W2601563721 hasConcept C126322002 @default.
• W2601563721 hasConcept C143998085 @default.
• W2601563721 hasConcept C2776694085 @default.
• W2601563721 hasConcept C2776802502 @default.
• W2601563721 hasConcept C2778198053 @default.
• W2601563721 hasConcept C2779720357 @default.
• W2601563721 hasConcept C2779786085 @default.
• W2601563721 hasConcept C530470458 @default.
• W2601563721 hasConcept C71924100 @default.
• W2601563721 hasConcept C78085059 @default.
• W2601563721 hasConceptScore W2601563721C121608353 @default.
• W2601563721 hasConceptScore W2601563721C126322002 @default.
• W2601563721 hasConceptScore W2601563721C143998085 @default.
• W2601563721 hasConceptScore W2601563721C2776694085 @default.
• W2601563721 hasConceptScore W2601563721C2776802502 @default.
• W2601563721 hasConceptScore W2601563721C2778198053 @default.
• W2601563721 hasConceptScore W2601563721C2779720357 @default.
• W2601563721 hasConceptScore W2601563721C2779786085 @default.
• W2601563721 hasConceptScore W2601563721C530470458 @default.
• W2601563721 hasConceptScore W2601563721C71924100 @default.
• W2601563721 hasConceptScore W2601563721C78085059 @default.
• W2601563721 hasIssue "1" @default.
• W2601563721 hasLocation W26015637211 @default.
• W2601563721 hasLocation W26015637212 @default.
• W2601563721 hasLocation W26015637213 @default.
• W2601563721 hasLocation W26015637214 @default.
• W2601563721 hasOpenAccess W2601563721 @default.
• W2601563721 hasPrimaryLocation W26015637211 @default.
• W2601563721 hasRelatedWork W1976609613 @default.
• W2601563721 hasRelatedWork W2013223170 @default.
• W2601563721 hasRelatedWork W2020150632 @default.
• W2601563721 hasRelatedWork W202728438 @default.
• W2601563721 hasRelatedWork W2340442038 @default.
• W2601563721 hasRelatedWork W2524863578 @default.
• W2601563721 hasRelatedWork W2591616149 @default.
• W2601563721 hasRelatedWork W2791179561 @default.
• W2601563721 hasRelatedWork W4210830689 @default.
• W2601563721 hasRelatedWork W4212973790 @default.
• W2601563721 hasVolume "20" @default.
• W2601563721 isParatext "false" @default.

• next